Trial Profile
Apatinib combined with pemetrexed plus cisplatin as the first-line treatment of patients with negative diver gene advanced non-squamous non-small cell lung cancer: a single - center and single - arm clinical study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Jun 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2018 New trial record